Opportunities and challenges for human papillomavirus vaccination in China

Zhao, Chao; Zhao, Yun; Li, Jingran; Li, Mingzhu; Shi, Yujing; Wei, Lihui

doi:10.1080/21645515.2024.2329450

Cited by 8 publications

(2 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…) 0 (0.0) 0.193 HMB 0 (0.0) 0 (0.0) 0 (0.0) 1.000 Dysmenorrhea 2 (0.3) 12 (0.) 0 (0.0) 1.000 IMB 1 (0.1) 0 (0.0) 0 (0.0) 1.000 1 Received the HPV vaccine before COVID-19 vaccination. 2 The HPV and COVID-19 vaccines were administered concurrently.…”

Section: Aes Associated With the Covid-19 Vaccine Based On Different ...mentioning

confidence: 99%

“…Since 2022, five human papillomavirus (HPV) vaccines have been licensed by the Chinese Food and Drug Administration (CFDA) and used in mainland China, while four Vaccines 2024, 12, 673 2 of 15 HPV vaccines have been licensed for use in other countries [1,2]. The efficacy of HPV vaccines in preventing cervical cancer and precancerous lesions is well recognized [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety Assessment of Concurrent Vaccination with the HPV Vaccine and the COVID-19 Vaccine in Fujian Province, China: A Retrospective Study

Zhang,

Dong

et al. 2024

Vaccines

View full text Add to dashboard Cite

During acute respiratory infections, women may concurrently receive human papillomavirus (HPV) and respiratory vaccines, as observed during the coronavirus disease 2019 (COVID-19) pandemic in China. However, few studies have assessed the safety of such concurrent administration, which could impact HPV vaccination schedules. This study analyzes the safety and optimal sequence of concurrent HPV and COVID-19 vaccinations. For this purpose, we surveyed women with both vaccines from January to October 2023 in Fujian Province, China. During this process, we collected vaccination history and adverse event (AE) data via telephone or interviews. Participants were grouped as Before, Concurrent, or After based on their vaccination sequence. A Chi-squared test, exact Fisher tests, and logistic regression were used to analyze the incidence of AEs and factors influencing vaccine safety. Overall, 1416 eligible participants were included. Although overall AE risk with the HPV vaccine was unaffected by vaccination sequence, individual AEs varied statistically between groups, including pain at the vaccination site (p < 0.001) and prolonged menstruation duration (p = 0.003). Based on the results, the optimal sequence would be to receive the HPV vaccine after the COVID-19 vaccine (After group). This insight may guide future emergency vaccination sequences for HPV and other respiratory infectious diseases.

show abstract

Section: Aes Associated With the Covid-19 Vaccine Based On Different ...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Safety Assessment of Concurrent Vaccination with the HPV Vaccine and the COVID-19 Vaccine in Fujian Province, China: A Retrospective Study

Zhang,

Dong

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

Unveiling the seroprevalence of human papillomavirus in Guangdong, China: Implications for vaccination strategies

Hu,

Chen,

Lin

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Seroepidemiological characteristics of human papillomavirus (HPV) in community residents reflect natural infection and can guide the reform of vaccination programs. A population‐based serological survey was conducted in Guangdong Province. Serum anti‐HPV IgG antibody levels were determined by an ELISA. Neutralizing antibodies against HPV6, 11, 16, and 18 were detected via a pseudovirus‐based neutralization assay (PBNA). A total of 5122 serum samples were collected from community residents, including 1989 males and 3133 females, in three cities of Guangdong Province. The rate of HPV IgG antibody positivity in females was 5.39% (95% CI: 4.6–6.2), which was greater than that in males (2.36%; 95% CI: 1.7–3.1). HPV IgG antibodies were more frequently detected in females aged 51–60 years (11.30%; 95% CI: 7.6–16.0), whereas in males, the detection increased with age and reached 4.94% (95% CI: 2.8–6.9) in the group aged ≥71 years. The seropositivity of neutralizing antibodies against HPV6 and 11 was greater than that against HPV16 and 18. The serum neutralizing antibody titers in individuals who received three doses of a vaccine were 7‐ to 12‐fold greater than those in individuals who did not receive the vaccine. The neutralizing antibody titers slightly decreased within 40 months and ranged from 0.038 to 0.057 log ED50 per month. A moderate consistency between the HPV ELISA and PBNA results was observed (Kappa score = 0.49, r = 0.249, 0.635, 0.382, and 0.466 for HPV6, 11, 16, and 18, respectively). The HPV seropositivity rate among healthy residents of Guangdong Province was found to be low among children and adolescents and to increase with age. The serum neutralizing antibody titers were significantly greater in the vaccine group than that in the control group, and this difference persisted over time, which indicated promising protection against HPV infection.

show abstract

Trends in high-risk human papillomavirus infection and cervical cytology of women in Karamay City, 2012–2021

Jia,

Jiang,

Zhou

et al. 2024

Sex. Health

View full text Add to dashboard Cite

Background To describe the changes in cervical lesions prevalence and high-risk human papillomavirus (HR-HPV) infections from 2012 to 2021, which have never been reported before, to provide direction for the effective implementation of cervical cancer prevention measures. Methods This retrospective study included women aged >25 years who received either organised or opportunistic cervical HR-HPV screening from January 2012 to December 2021 in Karamay Central Hospital, Karamay, China. The patients were split into four groups according to age 25–35, 36–45, 46–55 and >55 years, respectively. The Joinpoint Regression Program was used to analyse the trends of HR-HPV infection and the detection of cervical lesions. Results Data from 85,429 women revealed a decline in HR-HPV infection rates across all age groups from 2012 to 2021. Although HR-HPV infection rates decreased, cervical lesion detection rates increased, although the proportion of cervical cancer in these lesions declined, likely due to enhanced awareness and HPV vaccination in Karamay. From 2012 to 2021, the prevalence of low-grade squamous intraepithelial lesions was 9.70%, and high-grade squamous intraepithelial lesions was 5.85%. HR-HPV infections were highest in the ≥55 years age group, with HPV52 (20.96%) being the most prevalent type. Conclusions In the past 10 years, the prevalence of HR-HPV infection has shown a decreasing trend, whereas the detection prevalence of cervical lesions has shown an upward trend among women in Karamay City. Importantly, particular emphasis should be placed on cervical cancer screening in women aged >55 years.

show abstract

Opportunities and challenges for human papillomavirus vaccination in China

Cited by 8 publications

References 92 publications

Safety Assessment of Concurrent Vaccination with the HPV Vaccine and the COVID-19 Vaccine in Fujian Province, China: A Retrospective Study

Safety Assessment of Concurrent Vaccination with the HPV Vaccine and the COVID-19 Vaccine in Fujian Province, China: A Retrospective Study

Unveiling the seroprevalence of human papillomavirus in Guangdong, China: Implications for vaccination strategies

Trends in high-risk human papillomavirus infection and cervical cytology of women in Karamay City, 2012–2021

Contact Info

Product

Resources

About